The randomised, double-blind, placebo-controlled trial enrolled 368 patients aged 12–80, randomised 1:1:1 to low-dose Tezspire, high-dose Tezspire or placebo as a subcutaneous injection every four weeks, alongside continued background EoE medication (PPIs and topical corticosteroids). At week 24, Tezspire achieved statistically significant, clinically meaningful improvement in histologic remission (peak eosinophil count ≤6 per high-power field) and in the frequency and severity of dysphagia, measured by the Dysphagia Symptom Questionnaire — with benefits sustained through week 52.

EoE is a chronic, progressive allergic inflammatory condition of the esophagus that causes dysphagia, food impaction and esophageal narrowing; nearly half of patients fail to achieve adequate control on current first-line options such as dietary restriction, topical steroids and PPIs. Tezspire, a first-in-class human monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP), is already approved for severe asthma and CRSwNP in more than 70 countries including the US, EU, China and Japan.

“The positive results […] reinforce our confidence in the differentiated mechanism of action of Tezspire,” stated Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.